The estimated Net Worth of Lex Bakker is at least $1.43 Milión dollars as of 2 July 2021. Mr. Bakker owns over 7,000 units of Merus N.V stock worth over $787,787 and over the last 5 years he sold MRUS stock worth over $81,253. In addition, he makes $565,320 as Chief Development Officer at Merus N.V.
Alexander has made over 15 trades of the Merus N.V stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of MRUS stock worth $13,510 on 2 July 2021.
The largest trade he's ever made was exercising 7,000 units of Merus N.V stock on 2 July 2021 worth over $13,510. On average, Alexander trades about 680 units every 30 days since 2020. As of 2 July 2021 he still owns at least 15,668 units of Merus N.V stock.
You can see the complete history of Mr. Bakker stock trades at the bottom of the page.
Alexander Berthold Hendrik Bakker Ph.D. serves as Chief Development Officer of the Company. His responsibilities include strategic scientific leadership, management of preclinical and clinical development and manufacturing, business development support, external collaboration and partnership management. Prior to joining Merus, Dr. Bakker directed preclinical and clinical development at Crucell N.V., a biotechnology company. Mr. Bakker holds a Ph.D. in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute.
As the Chief Development Officer of Merus N.V, the total compensation of Alexander Bakker at Merus N.V is $565,320. There are 4 executives at Merus N.V getting paid more, with Hui Liu having the highest compensation of $1,382,530.
Alexander Bakker is 54, he's been the Chief Development Officer of Merus N.V since 2010. There are 7 older and 7 younger executives at Merus N.V. The oldest executive at Merus N.V is Gregory Perry, 59, who is the Independent Non-Executive Vice Chairman of the Board.
Lex's mailing address filed with the SEC is C/O MERUS N.V., YALELAAN 62, UTRECHT, P7, 3584 CM.
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Merus N.V executives and other stock owners filed with the SEC include: